JP2008513459A

JP2008513459A - 骨同化物質を用いた骨疾患の治療方法

骨同化物質を用いた骨疾患の治療方法 Download PDF

Info

Publication number: JP2008513459A
Authority: JP; Japan
Prior art keywords: pthrp; bone; pth; day; patient
Prior art date: 2004-09-16
Legal status : Pending

Application number

JP2007532415A

Other languages

English (en)

Japanese (ja)

Inventor

アンドリューエフ．スチュアート

Original Assignee

オステオトロフィンリミテッドライアビリティーカンパニー

Priority date

2004-09-16

Filing date

2005-09-14

Publication date

2008-05-01

2005-09-14 Application filed by オステオトロフィンリミテッドライアビリティーカンパニー filed Critical オステオトロフィンリミテッドライアビリティーカンパニー

2008-05-01 Publication of JP2008513459A publication Critical patent/JP2008513459A/ja

Status Pending legal-status Critical Current

Links

210000000988 bone and bone Anatomy 0.000 title claims abstract description 234
238000000034 method Methods 0.000 title claims abstract description 138
208000020084 Bone disease Diseases 0.000 title claims description 7
230000001195 anabolic effect Effects 0.000 title description 43
239000000126 substance Substances 0.000 title description 27
102000043299 Parathyroid hormone-related Human genes 0.000 claims abstract description 290
208000001132 Osteoporosis Diseases 0.000 claims abstract description 59
208000029725 Metabolic bone disease Diseases 0.000 claims abstract description 11
208000030136 Marchiafava-Bignami Disease Diseases 0.000 claims abstract description 7
108700020797 Parathyroid Hormone-Related Proteins 0.000 claims abstract description 5
230000001965 increasing effect Effects 0.000 claims description 48
206010065687 Bone loss Diseases 0.000 claims description 22
208000005368 osteomalacia Diseases 0.000 claims description 7
208000013725 Chronic Kidney Disease-Mineral and Bone disease Diseases 0.000 claims description 4
201000006409 renal osteodystrophy Diseases 0.000 claims description 4
238000001356 surgical procedure Methods 0.000 claims description 3
238000011282 treatment Methods 0.000 abstract description 88
230000001976 improved effect Effects 0.000 abstract description 5
230000002265 prevention Effects 0.000 abstract description 4
101710123753 Parathyroid hormone-related protein Proteins 0.000 description 290
108090000445 Parathyroid hormone Proteins 0.000 description 218
102000003982 Parathyroid hormone Human genes 0.000 description 215
239000000199 parathyroid hormone Substances 0.000 description 214
229960001319 parathyroid hormone Drugs 0.000 description 196
108090000765 processed proteins & peptides Proteins 0.000 description 94
235000001014 amino acid Nutrition 0.000 description 82
230000027455 binding Effects 0.000 description 71
229940024606 amino acid Drugs 0.000 description 61
150000001413 amino acids Chemical class 0.000 description 60
230000000694 effects Effects 0.000 description 56
238000012360 testing method Methods 0.000 description 56
210000004027 cell Anatomy 0.000 description 54
125000003275 alpha amino acid group Chemical group 0.000 description 52
239000011575 calcium Substances 0.000 description 50
239000000902 placebo Substances 0.000 description 50
229940068196 placebo Drugs 0.000 description 50
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 49
229910052791 calcium Inorganic materials 0.000 description 49
102000004196 processed proteins & peptides Human genes 0.000 description 49
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 47
210000000170 cell membrane Anatomy 0.000 description 47
241001465754 Metazoa Species 0.000 description 45
239000012634 fragment Substances 0.000 description 39
OGBMKVWORPGQRR-UMXFMPSGSA-N teriparatide Chemical compound C([C@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)C(C)C)[C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CNC=N1 OGBMKVWORPGQRR-UMXFMPSGSA-N 0.000 description 38
241000700159 Rattus Species 0.000 description 37
102000005962 receptors Human genes 0.000 description 37
108020003175 receptors Proteins 0.000 description 37
229910052500 inorganic mineral Inorganic materials 0.000 description 36
239000011707 mineral Substances 0.000 description 36
210000002966 serum Anatomy 0.000 description 33
102000030621 adenylate cyclase Human genes 0.000 description 32
108060000200 adenylate cyclase Proteins 0.000 description 32
208000037147 Hypercalcaemia Diseases 0.000 description 29
230000004071 biological effect Effects 0.000 description 29
230000000148 hypercalcaemia Effects 0.000 description 29
208000030915 hypercalcemia disease Diseases 0.000 description 29
239000002287 radioligand Substances 0.000 description 29
238000006467 substitution reaction Methods 0.000 description 28
239000003263 anabolic agent Substances 0.000 description 27
229940124325 anabolic agent Drugs 0.000 description 27
230000004044 response Effects 0.000 description 27
230000015572 biosynthetic process Effects 0.000 description 23
206010017076 Fracture Diseases 0.000 description 22
230000024279 bone resorption Effects 0.000 description 22
238000002474 experimental method Methods 0.000 description 22
229920001184 polypeptide Polymers 0.000 description 22
229940078581 Bone resorption inhibitor Drugs 0.000 description 21
239000003814 drug Substances 0.000 description 21
229940079593 drug Drugs 0.000 description 20
208000006386 Bone Resorption Diseases 0.000 description 19
229940088597 hormone Drugs 0.000 description 19
239000005556 hormone Substances 0.000 description 19
238000005259 measurement Methods 0.000 description 19
239000012528 membrane Substances 0.000 description 19
210000004379 membrane Anatomy 0.000 description 19
150000001408 amides Chemical class 0.000 description 18
229940011871 estrogen Drugs 0.000 description 18
239000000262 estrogen Substances 0.000 description 18
230000011164 ossification Effects 0.000 description 18
108090000623 proteins and genes Proteins 0.000 description 18
210000001519 tissue Anatomy 0.000 description 18
230000008859 change Effects 0.000 description 17
239000000203 mixture Substances 0.000 description 17
239000000243 solution Substances 0.000 description 17
230000037182 bone density Effects 0.000 description 16
210000003734 kidney Anatomy 0.000 description 16
241000282465 Canis Species 0.000 description 15
101001135738 Homo sapiens Parathyroid hormone-related protein Proteins 0.000 description 15
108010049264 Teriparatide Proteins 0.000 description 15
238000010521 absorption reaction Methods 0.000 description 15
230000004913 activation Effects 0.000 description 15
239000000872 buffer Substances 0.000 description 15
239000000816 peptidomimetic Substances 0.000 description 15
239000011710 vitamin D Substances 0.000 description 15
229940046008 vitamin d Drugs 0.000 description 15
229930003316 Vitamin D Natural products 0.000 description 14
QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 14
201000010099 disease Diseases 0.000 description 14
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 14
238000009547 dual-energy X-ray absorptiometry Methods 0.000 description 14
238000011534 incubation Methods 0.000 description 14
230000000638 stimulation Effects 0.000 description 14
235000019166 vitamin D Nutrition 0.000 description 14
150000003710 vitamin D derivatives Chemical class 0.000 description 14
210000004705 lumbosacral region Anatomy 0.000 description 13
108010045398 parathyroid hormone-related peptide (1-36) Proteins 0.000 description 13
NNRMZXDHMCWWRV-RHBZDGMUSA-N (2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-aminopropanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-4-carboxybutanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-5-oxopentanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-3-carboxypropanoyl]amino]hexanoyl]amino]acetyl]amino]hexanoyl]amino]-3-hydroxypropanoyl]amino]-3-methylpentanoyl]amino]-5-oxopentanoyl]amino]-3-carboxypropanoyl]amino]-4-methylpentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-methylpentanoyl]amino]propanoyl]amino]-4-carboxybutanoyl]amino]-3-methylpentanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-3-hydroxybutanoyl]amino]propanoyl]amino]-4-carboxybutanoyl]amino]-3-methylpentanoic acid Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](C)N)C(C)C)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)CC)C1=CN=CN1 NNRMZXDHMCWWRV-RHBZDGMUSA-N 0.000 description 12
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 12
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
101710149426 Parathyroid hormone 2 receptor Proteins 0.000 description 12
102100030869 Parathyroid hormone 2 receptor Human genes 0.000 description 12
229930006000 Sucrose Natural products 0.000 description 12
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 12
230000002124 endocrine Effects 0.000 description 12
210000000963 osteoblast Anatomy 0.000 description 12
230000008569 process Effects 0.000 description 12
230000004936 stimulating effect Effects 0.000 description 12
239000005720 sucrose Substances 0.000 description 12
241000282412 Homo Species 0.000 description 11
108010058828 Parathyroid Hormone Receptors Proteins 0.000 description 11
102000006461 Parathyroid Hormone Receptors Human genes 0.000 description 11
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 11
238000004458 analytical method Methods 0.000 description 11
238000000338 in vitro Methods 0.000 description 11
210000003292 kidney cell Anatomy 0.000 description 11
201000008968 osteosarcoma Diseases 0.000 description 11
238000002360 preparation method Methods 0.000 description 11
229940126586 small molecule drug Drugs 0.000 description 11
241000894007 species Species 0.000 description 11
230000009870 specific binding Effects 0.000 description 11
238000010998 test method Methods 0.000 description 11
108010001478 Bacitracin Proteins 0.000 description 10
208000010392 Bone Fractures Diseases 0.000 description 10
229960003071 bacitracin Drugs 0.000 description 10
229930184125 bacitracin Natural products 0.000 description 10
CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 10
239000002617 bone density conservation agent Substances 0.000 description 10
230000010072 bone remodeling Effects 0.000 description 10
BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 10
230000007423 decrease Effects 0.000 description 10
238000012217 deletion Methods 0.000 description 10
230000037430 deletion Effects 0.000 description 10
210000002436 femur neck Anatomy 0.000 description 10
230000009871 nonspecific binding Effects 0.000 description 10
239000002773 nucleotide Substances 0.000 description 10
125000003729 nucleotide group Chemical group 0.000 description 10
210000002997 osteoclast Anatomy 0.000 description 10
235000018102 proteins Nutrition 0.000 description 10
102000004169 proteins and genes Human genes 0.000 description 10
210000000689 upper leg Anatomy 0.000 description 10
102000055006 Calcitonin Human genes 0.000 description 9
108060001064 Calcitonin Proteins 0.000 description 9
239000002250 absorbent Substances 0.000 description 9
230000008416 bone turnover Effects 0.000 description 9
229960004015 calcitonin Drugs 0.000 description 9
230000006870 function Effects 0.000 description 9
210000004394 hip joint Anatomy 0.000 description 9
239000007924 injection Substances 0.000 description 9
238000002347 injection Methods 0.000 description 9
239000002244 precipitate Substances 0.000 description 9
238000007619 statistical method Methods 0.000 description 9
238000007920 subcutaneous administration Methods 0.000 description 9
229940122361 Bisphosphonate Drugs 0.000 description 8
201000002980 Hyperparathyroidism Diseases 0.000 description 8
108091028043 Nucleic acid sequence Proteins 0.000 description 8
101150071808 PTHLH gene Proteins 0.000 description 8
101710180613 Parathyroid hormone/parathyroid hormone-related peptide receptor Proteins 0.000 description 8
-1 adhesion molecules Proteins 0.000 description 8
150000004663 bisphosphonates Chemical class 0.000 description 8
DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 8
239000002552 dosage form Substances 0.000 description 8
239000002609 medium Substances 0.000 description 8
150000007523 nucleic acids Chemical group 0.000 description 8
230000036470 plasma concentration Effects 0.000 description 8
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 8
238000007634 remodeling Methods 0.000 description 8
229940095743 selective estrogen receptor modulator Drugs 0.000 description 8
239000000333 selective estrogen receptor modulator Substances 0.000 description 8
108010039627 Aprotinin Proteins 0.000 description 7
102000004067 Osteocalcin Human genes 0.000 description 7
108090000573 Osteocalcin Proteins 0.000 description 7
239000000556 agonist Substances 0.000 description 7
229960004405 aprotinin Drugs 0.000 description 7
239000003795 chemical substances by application Substances 0.000 description 7
230000009137 competitive binding Effects 0.000 description 7
210000001624 hip Anatomy 0.000 description 7
238000001727 in vivo Methods 0.000 description 7
ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 7
239000003446 ligand Substances 0.000 description 7
238000009806 oophorectomy Methods 0.000 description 7
108010021152 pepBs1-Ac peptide Proteins 0.000 description 7
102000040430 polynucleotide Human genes 0.000 description 7
108091033319 polynucleotide Proteins 0.000 description 7
239000002157 polynucleotide Substances 0.000 description 7
238000010254 subcutaneous injection Methods 0.000 description 7
239000007929 subcutaneous injection Substances 0.000 description 7
239000006228 supernatant Substances 0.000 description 7
210000002303 tibia Anatomy 0.000 description 7
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 6
OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 description 6
102100036893 Parathyroid hormone Human genes 0.000 description 6
IIDJRNMFWXDHID-UHFFFAOYSA-N Risedronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CC1=CC=CN=C1 IIDJRNMFWXDHID-UHFFFAOYSA-N 0.000 description 6
238000007792 addition Methods 0.000 description 6
238000004364 calculation method Methods 0.000 description 6
230000001054 cortical effect Effects 0.000 description 6
238000009396 hybridization Methods 0.000 description 6
230000006872 improvement Effects 0.000 description 6
230000003834 intracellular effect Effects 0.000 description 6
239000000463 material Substances 0.000 description 6
238000013425 morphometry Methods 0.000 description 6
230000035772 mutation Effects 0.000 description 6
GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 6
230000009467 reduction Effects 0.000 description 6
230000002829 reductive effect Effects 0.000 description 6
238000013391 scatchard analysis Methods 0.000 description 6
239000011780 sodium chloride Substances 0.000 description 6
238000010532 solid phase synthesis reaction Methods 0.000 description 6
238000003786 synthesis reaction Methods 0.000 description 6
210000002700 urine Anatomy 0.000 description 6
XRASPMIURGNCCH-UHFFFAOYSA-N zoledronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CN1C=CN=C1 XRASPMIURGNCCH-UHFFFAOYSA-N 0.000 description 6
DBVJJBKOTRCVKF-UHFFFAOYSA-N Etidronic acid Chemical compound OP(=O)(O)C(O)(C)P(O)(O)=O DBVJJBKOTRCVKF-UHFFFAOYSA-N 0.000 description 5
108091006027 G proteins Proteins 0.000 description 5
102000030782 GTP binding Human genes 0.000 description 5
108091000058 GTP-Binding Proteins 0.000 description 5
101001135770 Homo sapiens Parathyroid hormone Proteins 0.000 description 5
101001135995 Homo sapiens Probable peptidyl-tRNA hydrolase Proteins 0.000 description 5
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 5
206010028980 Neoplasm Diseases 0.000 description 5
206010067482 No adverse event Diseases 0.000 description 5
229910019142 PO4 Inorganic materials 0.000 description 5
102100032256 Parathyroid hormone/parathyroid hormone-related peptide receptor Human genes 0.000 description 5
229940062527 alendronate Drugs 0.000 description 5
230000008827 biological function Effects 0.000 description 5
201000011510 cancer Diseases 0.000 description 5
238000006243 chemical reaction Methods 0.000 description 5
230000000295 complement effect Effects 0.000 description 5
230000009850 completed effect Effects 0.000 description 5
238000002591 computed tomography Methods 0.000 description 5
238000002247 constant time method Methods 0.000 description 5
230000006378 damage Effects 0.000 description 5
238000011161 development Methods 0.000 description 5
230000018109 developmental process Effects 0.000 description 5
231100000673 dose–response relationship Toxicity 0.000 description 5
230000012010 growth Effects 0.000 description 5
238000004519 manufacturing process Methods 0.000 description 5
239000003550 marker Substances 0.000 description 5
230000001009 osteoporotic effect Effects 0.000 description 5
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 5
235000021317 phosphate Nutrition 0.000 description 5
229960004622 raloxifene Drugs 0.000 description 5
238000012552 review Methods 0.000 description 5
229940089617 risedronate Drugs 0.000 description 5
230000011664 signaling Effects 0.000 description 5
150000003384 small molecules Chemical class 0.000 description 5
JZRAGGVVGLXXHF-UHFFFAOYSA-N thiohypofluorous acid;toluene Chemical compound SF.CC1=CC=CC=C1 JZRAGGVVGLXXHF-UHFFFAOYSA-N 0.000 description 5
238000002604 ultrasonography Methods 0.000 description 5
239000003981 vehicle Substances 0.000 description 5
229960004276 zoledronic acid Drugs 0.000 description 5
ZOWOHMFPXMYFKJ-WBTWNKCNSA-N (4S)-4-[[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-aminopropanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-4-carboxybutanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-5-oxopentanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-3-carboxypropanoyl]amino]hexanoyl]amino]acetyl]amino]hexanoyl]amino]-3-hydroxypropanoyl]amino]-3-methylpentanoyl]amino]-5-oxopentanoyl]amino]-3-carboxypropanoyl]amino]-4-methylpentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-methylpentanoyl]amino]propanoyl]amino]-5-[[(2S,3S)-1-[[(2S)-1-[[(2S,3R)-1-[[(1S)-1-carboxyethyl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-5-oxopentanoic acid Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](C)N)C(C)C)[C@@H](C)CC)C1=CN=CN1 ZOWOHMFPXMYFKJ-WBTWNKCNSA-N 0.000 description 4
101001135732 Bos taurus Parathyroid hormone Proteins 0.000 description 4
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
ZAHDXEIQWWLQQL-IHRRRGAJSA-N Deoxypyridinoline Chemical compound OC(=O)[C@@H](N)CCCC[N+]1=CC(O)=C(C[C@H](N)C([O-])=O)C(CC[C@H](N)C(O)=O)=C1 ZAHDXEIQWWLQQL-IHRRRGAJSA-N 0.000 description 4
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 4
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
102000015696 Interleukins Human genes 0.000 description 4
108010063738 Interleukins Proteins 0.000 description 4
108010023244 Lactoperoxidase Proteins 0.000 description 4
102000045576 Lactoperoxidases Human genes 0.000 description 4
206010028813 Nausea Diseases 0.000 description 4
OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 4
NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 4
DKJJVAGXPKPDRL-UHFFFAOYSA-N Tiludronic acid Chemical compound OP(O)(=O)C(P(O)(O)=O)SC1=CC=C(Cl)C=C1 DKJJVAGXPKPDRL-UHFFFAOYSA-N 0.000 description 4
239000006096 absorbing agent Substances 0.000 description 4
230000002411 adverse Effects 0.000 description 4
230000001270 agonistic effect Effects 0.000 description 4
125000000539 amino acid group Chemical group 0.000 description 4
230000003042 antagnostic effect Effects 0.000 description 4
230000000123 anti-resoprtive effect Effects 0.000 description 4
238000003556 assay Methods 0.000 description 4
230000008901 benefit Effects 0.000 description 4
210000004369 blood Anatomy 0.000 description 4
239000008280 blood Substances 0.000 description 4
108700027323 bovine parathyroid hormone Proteins 0.000 description 4
230000001593 cAMP accumulation Effects 0.000 description 4
238000004422 calculation algorithm Methods 0.000 description 4
238000012512 characterization method Methods 0.000 description 4
208000020832 chronic kidney disease Diseases 0.000 description 4
208000022831 chronic renal failure syndrome Diseases 0.000 description 4
150000001875 compounds Chemical class 0.000 description 4
238000004590 computer program Methods 0.000 description 4
238000011960 computer-aided design Methods 0.000 description 4
229940109239 creatinine Drugs 0.000 description 4
238000007405 data analysis Methods 0.000 description 4
229940009626 etidronate Drugs 0.000 description 4
238000011010 flushing procedure Methods 0.000 description 4
210000000245 forearm Anatomy 0.000 description 4
239000003102 growth factor Substances 0.000 description 4
102000058004 human PTH Human genes 0.000 description 4
238000003780 insertion Methods 0.000 description 4
230000037431 insertion Effects 0.000 description 4
230000003993 interaction Effects 0.000 description 4
229940057428 lactoperoxidase Drugs 0.000 description 4
230000007774 longterm Effects 0.000 description 4
230000009245 menopause Effects 0.000 description 4
230000004048 modification Effects 0.000 description 4
238000012986 modification Methods 0.000 description 4
230000008693 nausea Effects 0.000 description 4
230000002188 osteogenic effect Effects 0.000 description 4
WRUUGTRCQOWXEG-UHFFFAOYSA-N pamidronate Chemical compound NCCC(O)(P(O)(O)=O)P(O)(O)=O WRUUGTRCQOWXEG-UHFFFAOYSA-N 0.000 description 4
239000010452 phosphate Substances 0.000 description 4
239000011574 phosphorus Substances 0.000 description 4
229910052698 phosphorus Inorganic materials 0.000 description 4
239000000047 product Substances 0.000 description 4
230000001737 promoting effect Effects 0.000 description 4
238000004007 reversed phase HPLC Methods 0.000 description 4
208000007442 rickets Diseases 0.000 description 4
238000003860 storage Methods 0.000 description 4
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
230000002485 urinary effect Effects 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
241000283690 Bos taurus Species 0.000 description 3
102000008186 Collagen Human genes 0.000 description 3
108010035532 Collagen Proteins 0.000 description 3
IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 3
QIVBCDIJIAJPQS-SECBINFHSA-N D-tryptophane Chemical compound C1=CC=C2C(C[C@@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-SECBINFHSA-N 0.000 description 3
108020004414 DNA Proteins 0.000 description 3
102000004190 Enzymes Human genes 0.000 description 3
108090000790 Enzymes Proteins 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 3
XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 3
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 3
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 3
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 3
AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 3
GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 3
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
241000699670 Mus sp. Species 0.000 description 3
206010049088 Osteopenia Diseases 0.000 description 3
102000003923 Protein Kinase C Human genes 0.000 description 3
108090000315 Protein Kinase C Proteins 0.000 description 3
230000010799 Receptor Interactions Effects 0.000 description 3
208000005770 Secondary Hyperparathyroidism Diseases 0.000 description 3
238000000692 Student's t-test Methods 0.000 description 3
IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 3
230000002159 abnormal effect Effects 0.000 description 3
230000009471 action Effects 0.000 description 3
230000004075 alteration Effects 0.000 description 3
210000002449 bone cell Anatomy 0.000 description 3
239000005388 borosilicate glass Substances 0.000 description 3
210000004556 brain Anatomy 0.000 description 3
210000004899 c-terminal region Anatomy 0.000 description 3
229960005069 calcium Drugs 0.000 description 3
230000001925 catabolic effect Effects 0.000 description 3
230000015556 catabolic process Effects 0.000 description 3
229920001436 collagen Polymers 0.000 description 3
229940035811 conjugated estrogen Drugs 0.000 description 3
229940095074 cyclic amp Drugs 0.000 description 3
230000003247 decreasing effect Effects 0.000 description 3
238000001739 density measurement Methods 0.000 description 3
239000002158 endotoxin Substances 0.000 description 3
238000005516 engineering process Methods 0.000 description 3
229940088598 enzyme Drugs 0.000 description 3
239000000284 extract Substances 0.000 description 3
230000002068 genetic effect Effects 0.000 description 3
238000007689 inspection Methods 0.000 description 3
GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 3
108010052968 leupeptin Proteins 0.000 description 3
239000007788 liquid Substances 0.000 description 3
239000011159 matrix material Substances 0.000 description 3
230000001404 mediated effect Effects 0.000 description 3
230000002503 metabolic effect Effects 0.000 description 3
238000012261 overproduction Methods 0.000 description 3
229940046231 pamidronate Drugs 0.000 description 3
210000000496 pancreas Anatomy 0.000 description 3
230000037361 pathway Effects 0.000 description 3
229950000964 pepstatin Drugs 0.000 description 3
108010091212 pepstatin Proteins 0.000 description 3
FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 3
239000008194 pharmaceutical composition Substances 0.000 description 3
239000000546 pharmaceutical excipient Substances 0.000 description 3
230000003389 potentiating effect Effects 0.000 description 3
231100001271 preclinical toxicology Toxicity 0.000 description 3
239000002243 precursor Substances 0.000 description 3
239000013615 primer Substances 0.000 description 3
238000012545 processing Methods 0.000 description 3
230000002062 proliferating effect Effects 0.000 description 3
238000007363 ring formation reaction Methods 0.000 description 3
239000011734 sodium Substances 0.000 description 3
229940019375 tiludronate Drugs 0.000 description 3
239000003643 water by type Substances 0.000 description 3
102000002260 Alkaline Phosphatase Human genes 0.000 description 2
108020004774 Alkaline Phosphatase Proteins 0.000 description 2
DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
101000606274 Bos taurus Parathyroid hormone-related protein Proteins 0.000 description 2
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
102000008130 Cyclic AMP-Dependent Protein Kinases Human genes 0.000 description 2
102000004127 Cytokines Human genes 0.000 description 2
108090000695 Cytokines Proteins 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
ZQZFYGIXNQKOAV-OCEACIFDSA-N Droloxifene Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=C(O)C=CC=1)\C1=CC=C(OCCN(C)C)C=C1 ZQZFYGIXNQKOAV-OCEACIFDSA-N 0.000 description 2
102000051325 Glucagon Human genes 0.000 description 2
108060003199 Glucagon Proteins 0.000 description 2
108010007979 Glycocholic Acid Proteins 0.000 description 2
206010020100 Hip fracture Diseases 0.000 description 2
101000589873 Homo sapiens Parathyroid hormone/parathyroid hormone-related peptide receptor Proteins 0.000 description 2
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 2
JJKOTMDDZAJTGQ-DQSJHHFOSA-N Idoxifene Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN2CCCC2)=CC=1)/C1=CC=C(I)C=C1 JJKOTMDDZAJTGQ-DQSJHHFOSA-N 0.000 description 2
229930182816 L-glutamine Natural products 0.000 description 2
102000008072 Lymphokines Human genes 0.000 description 2
108010074338 Lymphokines Proteins 0.000 description 2
206010031127 Orthostatic hypotension Diseases 0.000 description 2
229930182555 Penicillin Natural products 0.000 description 2
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
101001135735 Rattus norvegicus Parathyroid hormone-related protein Proteins 0.000 description 2
208000001647 Renal Insufficiency Diseases 0.000 description 2
108010086019 Secretin Proteins 0.000 description 2
102100037505 Secretin Human genes 0.000 description 2
229940083324 Selective androgen receptor modulator Drugs 0.000 description 2
102000013275 Somatomedins Human genes 0.000 description 2
206010041541 Spinal compression fracture Diseases 0.000 description 2
102000009618 Transforming Growth Factors Human genes 0.000 description 2
108010009583 Transforming Growth Factors Proteins 0.000 description 2
229920004890 Triton X-100 Polymers 0.000 description 2
239000013504 Triton X-100 Substances 0.000 description 2
108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
102000014384 Type C Phospholipases Human genes 0.000 description 2
108010079194 Type C Phospholipases Proteins 0.000 description 2
108010003205 Vasoactive Intestinal Peptide Proteins 0.000 description 2
102000055135 Vasoactive Intestinal Peptide Human genes 0.000 description 2
206010047626 Vitamin D Deficiency Diseases 0.000 description 2
238000002441 X-ray diffraction Methods 0.000 description 2
239000002253 acid Substances 0.000 description 2
239000000443 aerosol Substances 0.000 description 2
230000032683 aging Effects 0.000 description 2
238000000540 analysis of variance Methods 0.000 description 2
239000005557 antagonist Substances 0.000 description 2
238000013459 approach Methods 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
235000009582 asparagine Nutrition 0.000 description 2
229960001230 asparagine Drugs 0.000 description 2
239000012148 binding buffer Substances 0.000 description 2
230000031018 biological processes and functions Effects 0.000 description 2
239000002639 bone cement Substances 0.000 description 2
210000000481 breast Anatomy 0.000 description 2
159000000007 calcium salts Chemical class 0.000 description 2
210000000845 cartilage Anatomy 0.000 description 2
238000003776 cleavage reaction Methods 0.000 description 2
108010049937 collagen type I trimeric cross-linked peptide Proteins 0.000 description 2
230000002860 competitive effect Effects 0.000 description 2
238000012937 correction Methods 0.000 description 2
230000007547 defect Effects 0.000 description 2
230000007812 deficiency Effects 0.000 description 2
238000006731 degradation reaction Methods 0.000 description 2
238000013461 design Methods 0.000 description 2
238000010494 dissociation reaction Methods 0.000 description 2
230000005593 dissociations Effects 0.000 description 2
VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 2
PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 2
229950004203 droloxifene Drugs 0.000 description 2
239000006274 endogenous ligand Substances 0.000 description 2
238000011067 equilibration Methods 0.000 description 2
102000015694 estrogen receptors Human genes 0.000 description 2
108010038795 estrogen receptors Proteins 0.000 description 2
230000007717 exclusion Effects 0.000 description 2
230000002349 favourable effect Effects 0.000 description 2
239000012091 fetal bovine serum Substances 0.000 description 2
230000001605 fetal effect Effects 0.000 description 2
239000011521 glass Substances 0.000 description 2
MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 2
229960004666 glucagon Drugs 0.000 description 2
239000003862 glucocorticoid Substances 0.000 description 2
RFDAIACWWDREDC-FRVQLJSFSA-N glycocholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 RFDAIACWWDREDC-FRVQLJSFSA-N 0.000 description 2
230000036541 health Effects 0.000 description 2
230000003054 hormonal effect Effects 0.000 description 2
102000051132 human PTH1R Human genes 0.000 description 2
229910052739 hydrogen Inorganic materials 0.000 description 2
229960002591 hydroxyproline Drugs 0.000 description 2
230000002267 hypothalamic effect Effects 0.000 description 2
229950002248 idoxifene Drugs 0.000 description 2
239000003112 inhibitor Substances 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
230000000977 initiatory effect Effects 0.000 description 2
238000007912 intraperitoneal administration Methods 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
210000000231 kidney cortex Anatomy 0.000 description 2
201000006370 kidney failure Diseases 0.000 description 2
JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 description 2
XZEUAXYWNKYKPL-WDYNHAJCSA-N levormeloxifene Chemical compound C1([C@H]2[C@@H](C3=CC=C(C=C3OC2(C)C)OC)C=2C=CC(OCCN3CCCC3)=CC=2)=CC=CC=C1 XZEUAXYWNKYKPL-WDYNHAJCSA-N 0.000 description 2
229950002728 levormeloxifene Drugs 0.000 description 2
230000035800 maturation Effects 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
229930182817 methionine Natural products 0.000 description 2
235000013336 milk Nutrition 0.000 description 2
239000008267 milk Substances 0.000 description 2
210000004080 milk Anatomy 0.000 description 2
210000002864 mononuclear phagocyte Anatomy 0.000 description 2
235000015097 nutrients Nutrition 0.000 description 2
201000008482 osteoarthritis Diseases 0.000 description 2
230000001582 osteoblastic effect Effects 0.000 description 2
RRBCHMCWWOHRQL-UMXFMPSGSA-N parathyroid hormone (1-34)amide Chemical compound C([C@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)C(C)C)[C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)C1=CN=CN1 RRBCHMCWWOHRQL-UMXFMPSGSA-N 0.000 description 2
108010027662 parathyroid hormone-related protein (1-141) Proteins 0.000 description 2
238000007911 parenteral administration Methods 0.000 description 2
230000007310 pathophysiology Effects 0.000 description 2
229940049954 penicillin Drugs 0.000 description 2
239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
230000004962 physiological condition Effects 0.000 description 2
229920000642 polymer Polymers 0.000 description 2
238000003752 polymerase chain reaction Methods 0.000 description 2
108010091624 preproparathormone Proteins 0.000 description 2
230000009290 primary effect Effects 0.000 description 2
238000000159 protein binding assay Methods 0.000 description 2
230000008929 regeneration Effects 0.000 description 2
238000011069 regeneration method Methods 0.000 description 2
238000009877 rendering Methods 0.000 description 2
230000007017 scission Effects 0.000 description 2
229960002101 secretin Drugs 0.000 description 2
OWMZNFCDEHGFEP-NFBCVYDUSA-N secretin human Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(N)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)C1=CC=CC=C1 OWMZNFCDEHGFEP-NFBCVYDUSA-N 0.000 description 2
239000000849 selective androgen receptor modulator Substances 0.000 description 2
238000011452 sequencing regimen Methods 0.000 description 2
230000019491 signal transduction Effects 0.000 description 2
229960005322 streptomycin Drugs 0.000 description 2
230000009469 supplementation Effects 0.000 description 2
239000000725 suspension Substances 0.000 description 2
208000024891 symptom Diseases 0.000 description 2
208000011580 syndromic disease Diseases 0.000 description 2
230000009885 systemic effect Effects 0.000 description 2
229940037128 systemic glucocorticoids Drugs 0.000 description 2
229960001603 tamoxifen Drugs 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
239000005495 thyroid hormone Substances 0.000 description 2
229940036555 thyroid hormone Drugs 0.000 description 2
XFCLJVABOIYOMF-QPLCGJKRSA-N toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 description 2
229960005026 toremifene Drugs 0.000 description 2
231100000440 toxicity profile Toxicity 0.000 description 2
FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 2
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 2
102000003390 tumor necrosis factor Human genes 0.000 description 2
150000003668 tyrosines Chemical class 0.000 description 2
229940088594 vitamin Drugs 0.000 description 2
229930003231 vitamin Natural products 0.000 description 2
235000013343 vitamin Nutrition 0.000 description 2
239000011782 vitamin Substances 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
230000004584 weight gain Effects 0.000 description 2
235000019786 weight gain Nutrition 0.000 description 2
DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 description 1
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
VUBUAHHUDGCHIN-LPJXTDOQSA-N (2S)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-aminopropanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-4-carboxybutanoyl]amino]-3-methylpentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-oxobutanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]hexanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-4-carboxybutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-carboxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-methylpentanoyl]amino]-5-carbamimidamidopentanoyl]amino]hexanoyl]amino]hexanoyl]amino]-4-methylpentanoyl]amino]-5-oxopentanoyl]amino]butanedioic acid Chemical compound CC[C@H](C)[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](C)N)C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O VUBUAHHUDGCHIN-LPJXTDOQSA-N 0.000 description 1
KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
MRXDGVXSWIXTQL-HYHFHBMOSA-N (2s)-2-[[(1s)-1-(2-amino-1,4,5,6-tetrahydropyrimidin-6-yl)-2-[[(2s)-4-methyl-1-oxo-1-[[(2s)-1-oxo-3-phenylpropan-2-yl]amino]pentan-2-yl]amino]-2-oxoethyl]carbamoylamino]-3-phenylpropanoic acid Chemical compound C([C@H](NC(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C=O)C1NC(N)=NCC1)C(O)=O)C1=CC=CC=C1 MRXDGVXSWIXTQL-HYHFHBMOSA-N 0.000 description 1
NJYFRQQXXXRJHK-UHFFFAOYSA-N (4-aminophenyl) thiocyanate Chemical compound NC1=CC=C(SC#N)C=C1 NJYFRQQXXXRJHK-UHFFFAOYSA-N 0.000 description 1
108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
GMRQFYUYWCNGIN-ZVUFCXRFSA-N 1,25-dihydroxy vitamin D3 Chemical compound C1([C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=CC=C1C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-ZVUFCXRFSA-N 0.000 description 1
RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 description 1
YKGRXSLQYRREKO-DFOPOJAZSA-N 101380-54-5 Chemical compound C([C@H](N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)C1=CC=CC=C1 YKGRXSLQYRREKO-DFOPOJAZSA-N 0.000 description 1
FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
BOFUZZAQNVYZFF-UHFFFAOYSA-N 2-(3-chlorophenyl)-3-methylmorpholine Chemical compound CC1NCCOC1C1=CC=CC(Cl)=C1 BOFUZZAQNVYZFF-UHFFFAOYSA-N 0.000 description 1
GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
CIHKVMHPDDJIIP-UHFFFAOYSA-N 2-methylperoxybenzoic acid Chemical compound COOC1=CC=CC=C1C(O)=O CIHKVMHPDDJIIP-UHFFFAOYSA-N 0.000 description 1
238000005084 2D-nuclear magnetic resonance Methods 0.000 description 1
APIXJSLKIYYUKG-UHFFFAOYSA-N 3 Isobutyl 1 methylxanthine Chemical compound O=C1N(C)C(=O)N(CC(C)C)C2=C1N=CN2 APIXJSLKIYYUKG-UHFFFAOYSA-N 0.000 description 1
102100031126 6-phosphogluconolactonase Human genes 0.000 description 1
108010029731 6-phosphogluconolactonase Proteins 0.000 description 1
241000251468 Actinopterygii Species 0.000 description 1
JBMKAUGHUNFTOL-UHFFFAOYSA-N Aldoclor Chemical class C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NC=NS2(=O)=O JBMKAUGHUNFTOL-UHFFFAOYSA-N 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
206010003591 Ataxia Diseases 0.000 description 1
239000010755 BS 2869 Class G Substances 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
102000004031 Carboxy-Lyases Human genes 0.000 description 1
108090000489 Carboxy-Lyases Proteins 0.000 description 1
102000005572 Cathepsin A Human genes 0.000 description 1
108010059081 Cathepsin A Proteins 0.000 description 1
241001529572 Chaceon affinis Species 0.000 description 1
206010008479 Chest Pain Diseases 0.000 description 1
OLVPQBGMUGIKIW-UHFFFAOYSA-N Chymostatin Natural products C=1C=CC=CC=1CC(C=O)NC(=O)C(C(C)CC)NC(=O)C(C1NC(N)=NCC1)NC(=O)NC(C(O)=O)CC1=CC=CC=C1 OLVPQBGMUGIKIW-UHFFFAOYSA-N 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
108091026890 Coding region Proteins 0.000 description 1
102000012422 Collagen Type I Human genes 0.000 description 1
108010022452 Collagen Type I Proteins 0.000 description 1
108020004635 Complementary DNA Proteins 0.000 description 1
206010010214 Compression fracture Diseases 0.000 description 1
206010062344 Congenital musculoskeletal anomaly Diseases 0.000 description 1
206010010774 Constipation Diseases 0.000 description 1
MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
108010049894 Cyclic AMP-Dependent Protein Kinases Proteins 0.000 description 1
239000003155 DNA primer Substances 0.000 description 1
241000252212 Danio rerio Species 0.000 description 1
208000013558 Developmental Bone disease Diseases 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
206010012735 Diarrhoea Diseases 0.000 description 1
206010058314 Dysplasia Diseases 0.000 description 1
208000000059 Dyspnea Diseases 0.000 description 1
206010013975 Dyspnoeas Diseases 0.000 description 1
241000588724 Escherichia coli Species 0.000 description 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
208000010201 Exanthema Diseases 0.000 description 1
108700024394 Exon Proteins 0.000 description 1
238000001134 F-test Methods 0.000 description 1
206010016654 Fibrosis Diseases 0.000 description 1
241000287828 Gallus gallus Species 0.000 description 1
108010018962 Glucosephosphate Dehydrogenase Proteins 0.000 description 1
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
101000899361 Homo sapiens Bone morphogenetic protein 7 Proteins 0.000 description 1
101000975003 Homo sapiens Kallistatin Proteins 0.000 description 1
101001084254 Homo sapiens Peptidyl-tRNA hydrolase 2, mitochondrial Proteins 0.000 description 1
101001077723 Homo sapiens Serine protease inhibitor Kazal-type 6 Proteins 0.000 description 1
101000598103 Homo sapiens Tuberoinfundibular peptide of 39 residues Proteins 0.000 description 1
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
206010020707 Hyperparathyroidism primary Diseases 0.000 description 1
206010020880 Hypertrophy Diseases 0.000 description 1
208000001953 Hypotension Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
208000026350 Inborn Genetic disease Diseases 0.000 description 1
102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
108090001117 Insulin-Like Growth Factor II Proteins 0.000 description 1
102000048143 Insulin-Like Growth Factor II Human genes 0.000 description 1
229940122920 Kallikrein inhibitor Drugs 0.000 description 1
102100023012 Kallistatin Human genes 0.000 description 1
ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
102000002704 Leucyl aminopeptidase Human genes 0.000 description 1
108010004098 Leucyl aminopeptidase Proteins 0.000 description 1
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
102000043136 MAP kinase family Human genes 0.000 description 1
108091054455 MAP kinase family Proteins 0.000 description 1
206010025476 Malabsorption Diseases 0.000 description 1
208000004155 Malabsorption Syndromes Diseases 0.000 description 1
206010064912 Malignant transformation Diseases 0.000 description 1
208000002720 Malnutrition Diseases 0.000 description 1
102000018697 Membrane Proteins Human genes 0.000 description 1
108010052285 Membrane Proteins Proteins 0.000 description 1
206010061291 Mineral deficiency Diseases 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
208000007101 Muscle Cramp Diseases 0.000 description 1
HDFGOPSGAURCEO-UHFFFAOYSA-N N-ethylmaleimide Chemical compound CCN1C(=O)C=CC1=O HDFGOPSGAURCEO-UHFFFAOYSA-N 0.000 description 1
239000004677 Nylon Substances 0.000 description 1
108091034117 Oligonucleotide Proteins 0.000 description 1
208000002565 Open Fractures Diseases 0.000 description 1
102000052812 Ornithine decarboxylases Human genes 0.000 description 1
108700005126 Ornithine decarboxylases Proteins 0.000 description 1
208000010191 Osteitis Deformans Diseases 0.000 description 1
208000008558 Osteophyte Diseases 0.000 description 1
239000007977 PBT buffer Substances 0.000 description 1
208000027868 Paget disease Diseases 0.000 description 1
208000000821 Parathyroid Neoplasms Diseases 0.000 description 1
206010033964 Parathyroid tumour benign Diseases 0.000 description 1
108010033276 Peptide Fragments Proteins 0.000 description 1
102000007079 Peptide Fragments Human genes 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
239000004743 Polypropylene Substances 0.000 description 1
102000017033 Porins Human genes 0.000 description 1
108010013381 Porins Proteins 0.000 description 1
201000000981 Primary Hyperparathyroidism Diseases 0.000 description 1
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
108010059712 Pronase Proteins 0.000 description 1
229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
102000001253 Protein Kinase Human genes 0.000 description 1
108010076504 Protein Sorting Signals Proteins 0.000 description 1
LCYXYLLJXMAEMT-SAXRGWBVSA-N Pyridinoline Chemical compound OC(=O)[C@@H](N)CCC1=C[N+](C[C@H](O)CC[C@H](N)C([O-])=O)=CC(O)=C1C[C@H](N)C(O)=O LCYXYLLJXMAEMT-SAXRGWBVSA-N 0.000 description 1
208000006265 Renal cell carcinoma Diseases 0.000 description 1
208000027790 Rib fracture Diseases 0.000 description 1
206010039984 Senile osteoporosis Diseases 0.000 description 1
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
206010072610 Skeletal dysplasia Diseases 0.000 description 1
208000005392 Spasm Diseases 0.000 description 1
208000013201 Stress fracture Diseases 0.000 description 1
239000004809 Teflon Substances 0.000 description 1
229920006362 Teflon® Polymers 0.000 description 1
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
239000004473 Threonine Substances 0.000 description 1
AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
108090000631 Trypsin Proteins 0.000 description 1
102000004142 Trypsin Human genes 0.000 description 1
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
102100036964 Tuberoinfundibular peptide of 39 residues Human genes 0.000 description 1
208000036029 Uterine contractions during pregnancy Diseases 0.000 description 1
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
241000700605 Viruses Species 0.000 description 1
206010047700 Vomiting Diseases 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
206010048049 Wrist fracture Diseases 0.000 description 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
210000004490 abdominal subcutaneous fat Anatomy 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
238000002835 absorbance Methods 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
229940037127 actonel Drugs 0.000 description 1
238000007605 air drying Methods 0.000 description 1
235000004279 alanine Nutrition 0.000 description 1
230000000172 allergic effect Effects 0.000 description 1
230000003321 amplification Effects 0.000 description 1
239000003098 androgen Substances 0.000 description 1
229940030486 androgens Drugs 0.000 description 1
238000002583 angiography Methods 0.000 description 1
230000003466 anti-cipated effect Effects 0.000 description 1
230000002968 anti-fracture Effects 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
238000004380 ashing Methods 0.000 description 1
150000001507 asparagine derivatives Chemical group 0.000 description 1
235000003704 aspartic acid Nutrition 0.000 description 1
208000010668 atopic eczema Diseases 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
230000003385 bacteriostatic effect Effects 0.000 description 1
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
239000012620 biological material Substances 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
230000008512 biological response Effects 0.000 description 1
230000033558 biomineral tissue development Effects 0.000 description 1
230000000740 bleeding effect Effects 0.000 description 1
238000009534 blood test Methods 0.000 description 1
230000036760 body temperature Effects 0.000 description 1
230000037396 body weight Effects 0.000 description 1
238000007470 bone biopsy Methods 0.000 description 1
230000014461 bone development Effects 0.000 description 1
210000001185 bone marrow Anatomy 0.000 description 1
230000004097 bone metabolism Effects 0.000 description 1
230000018678 bone mineralization Effects 0.000 description 1
230000010478 bone regeneration Effects 0.000 description 1
230000003491 cAMP production Effects 0.000 description 1
238000010804 cDNA synthesis Methods 0.000 description 1
DEGAKNSWVGKMLS-UHFFFAOYSA-N calcein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(CN(CC(O)=O)CC(O)=O)=C(O)C=C1OC1=C2C=C(CN(CC(O)=O)CC(=O)O)C(O)=C1 DEGAKNSWVGKMLS-UHFFFAOYSA-N 0.000 description 1
230000002308 calcification Effects 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
230000004094 calcium homeostasis Effects 0.000 description 1
230000003913 calcium metabolism Effects 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229940069978 calcium supplement Drugs 0.000 description 1
238000007675 cardiac surgery Methods 0.000 description 1
239000000969 carrier Substances 0.000 description 1
150000001768 cations Chemical class 0.000 description 1
230000001364 causal effect Effects 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
230000003915 cell function Effects 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
230000003833 cell viability Effects 0.000 description 1
230000036755 cellular response Effects 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
210000003710 cerebral cortex Anatomy 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
108010086192 chymostatin Proteins 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
229940110456 cocoa butter Drugs 0.000 description 1
235000019868 cocoa butter Nutrition 0.000 description 1
229960005188 collagen Drugs 0.000 description 1
239000002299 complementary DNA Substances 0.000 description 1
238000013329 compounding Methods 0.000 description 1
238000012669 compression test Methods 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
230000009146 cooperative binding Effects 0.000 description 1
229920001577 copolymer Polymers 0.000 description 1
229960004544 cortisone Drugs 0.000 description 1
239000013078 crystal Substances 0.000 description 1
210000004748 cultured cell Anatomy 0.000 description 1
238000005520 cutting process Methods 0.000 description 1
208000031513 cyst Diseases 0.000 description 1
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
235000018417 cysteine Nutrition 0.000 description 1
230000002380 cytological effect Effects 0.000 description 1
230000001086 cytosolic effect Effects 0.000 description 1
239000007857 degradation product Substances 0.000 description 1
230000018044 dehydration Effects 0.000 description 1
238000006297 dehydration reaction Methods 0.000 description 1
229940009976 deoxycholate Drugs 0.000 description 1
KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
238000001514 detection method Methods 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
238000000502 dialysis Methods 0.000 description 1
210000003275 diaphysis Anatomy 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
230000037213 diet Effects 0.000 description 1
235000015872 dietary supplement Nutrition 0.000 description 1
230000029087 digestion Effects 0.000 description 1
229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
231100000676 disease causative agent Toxicity 0.000 description 1
208000002173 dizziness Diseases 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
238000009510 drug design Methods 0.000 description 1
239000003596 drug target Substances 0.000 description 1
230000003503 early effect Effects 0.000 description 1
230000004821 effect on bone Effects 0.000 description 1
230000000668 effect on calcium Effects 0.000 description 1
230000002526 effect on cardiovascular system Effects 0.000 description 1
239000003792 electrolyte Substances 0.000 description 1
238000010828 elution Methods 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
210000002472 endoplasmic reticulum Anatomy 0.000 description 1
210000002889 endothelial cell Anatomy 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
238000001976 enzyme digestion Methods 0.000 description 1
JKKFKPJIXZFSSB-CBZIJGRNSA-N estrone 3-sulfate Chemical compound OS(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 JKKFKPJIXZFSSB-CBZIJGRNSA-N 0.000 description 1
DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
239000005038 ethylene vinyl acetate Substances 0.000 description 1
229940085363 evista Drugs 0.000 description 1
201000005884 exanthem Diseases 0.000 description 1
230000029142 excretion Effects 0.000 description 1
206010016165 failure to thrive Diseases 0.000 description 1
210000000501 femur body Anatomy 0.000 description 1
229940081104 fibrinogen / thrombin Drugs 0.000 description 1
230000004761 fibrosis Effects 0.000 description 1
230000003176 fibrotic effect Effects 0.000 description 1
210000004553 finger phalanx Anatomy 0.000 description 1
239000012530 fluid Substances 0.000 description 1
229940001490 fosamax Drugs 0.000 description 1
238000011990 functional testing Methods 0.000 description 1
108020001507 fusion proteins Proteins 0.000 description 1
102000037865 fusion proteins Human genes 0.000 description 1
230000005251 gamma ray Effects 0.000 description 1
238000003209 gene knockout Methods 0.000 description 1
208000016361 genetic disease Diseases 0.000 description 1
235000013922 glutamic acid Nutrition 0.000 description 1
239000004220 glutamic acid Substances 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
239000003163 gonadal steroid hormone Substances 0.000 description 1
230000036449 good health Effects 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
230000035876 healing Effects 0.000 description 1
210000002216 heart Anatomy 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
238000011540 hip replacement Methods 0.000 description 1
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
230000013632 homeostatic process Effects 0.000 description 1
102000046107 human BMP7 Human genes 0.000 description 1
229920002674 hyaluronan Polymers 0.000 description 1
229960003160 hyaluronic acid Drugs 0.000 description 1
XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
239000001863 hydroxypropyl cellulose Substances 0.000 description 1
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
230000000121 hypercalcemic effect Effects 0.000 description 1
230000036543 hypotension Effects 0.000 description 1
230000002989 hypothyroidism Effects 0.000 description 1
208000003532 hypothyroidism Diseases 0.000 description 1
238000002513 implantation Methods 0.000 description 1
230000004941 influx Effects 0.000 description 1
238000001802 infusion Methods 0.000 description 1
208000014674 injury Diseases 0.000 description 1
229960000367 inositol Drugs 0.000 description 1
230000010354 integration Effects 0.000 description 1
238000007917 intracranial administration Methods 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000007913 intrathecal administration Methods 0.000 description 1
238000007914 intraventricular administration Methods 0.000 description 1
238000011835 investigation Methods 0.000 description 1
230000026045 iodination Effects 0.000 description 1
238000006192 iodination reaction Methods 0.000 description 1
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
229960000310 isoleucine Drugs 0.000 description 1
208000017169 kidney disease Diseases 0.000 description 1
230000003907 kidney function Effects 0.000 description 1
239000008101 lactose Substances 0.000 description 1
150000002605 large molecules Chemical class 0.000 description 1
231100001231 less toxic Toxicity 0.000 description 1
231100000518 lethal Toxicity 0.000 description 1
230000001665 lethal effect Effects 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
238000012417 linear regression Methods 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
239000002502 liposome Substances 0.000 description 1
239000006193 liquid solution Substances 0.000 description 1
239000006194 liquid suspension Substances 0.000 description 1
229910052744 lithium Inorganic materials 0.000 description 1
229960001078 lithium Drugs 0.000 description 1
239000006210 lotion Substances 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
229920002521 macromolecule Polymers 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
230000036244 malformation Effects 0.000 description 1
230000036212 malign transformation Effects 0.000 description 1
230000003211 malignant effect Effects 0.000 description 1
230000001071 malnutrition Effects 0.000 description 1
235000000824 malnutrition Nutrition 0.000 description 1
208000027202 mammary Paget disease Diseases 0.000 description 1
238000004949 mass spectrometry Methods 0.000 description 1
238000001819 mass spectrum Methods 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
108020004999 messenger RNA Proteins 0.000 description 1
208000030159 metabolic disease Diseases 0.000 description 1
230000037353 metabolic pathway Effects 0.000 description 1
150000002741 methionine derivatives Chemical group 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
229940101566 miacalcin Drugs 0.000 description 1
230000005012 migration Effects 0.000 description 1
238000013508 migration Methods 0.000 description 1
238000002156 mixing Methods 0.000 description 1
230000004660 morphological change Effects 0.000 description 1
210000002200 mouth mucosa Anatomy 0.000 description 1
XTAZYLNFDRKIHJ-UHFFFAOYSA-N n,n-dioctyloctan-1-amine Chemical compound CCCCCCCCN(CCCCCCCC)CCCCCCCC XTAZYLNFDRKIHJ-UHFFFAOYSA-N 0.000 description 1
210000004898 n-terminal fragment Anatomy 0.000 description 1
150000002790 naphthalenes Chemical class 0.000 description 1
239000007923 nasal drop Substances 0.000 description 1
229940100662 nasal drops Drugs 0.000 description 1
238000013059 nephrectomy Methods 0.000 description 1
231100000957 no side effect Toxicity 0.000 description 1
231100000344 non-irritating Toxicity 0.000 description 1
231100000956 nontoxicity Toxicity 0.000 description 1
238000003199 nucleic acid amplification method Methods 0.000 description 1
235000016709 nutrition Nutrition 0.000 description 1
208000015380 nutritional deficiency disease Diseases 0.000 description 1
229920001778 nylon Polymers 0.000 description 1
229960002378 oftasceine Drugs 0.000 description 1
239000002674 ointment Substances 0.000 description 1
230000008520 organization Effects 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
230000001599 osteoclastic effect Effects 0.000 description 1
229940070020 other anabolic agent in atc Drugs 0.000 description 1
230000002611 ovarian Effects 0.000 description 1
210000001672 ovary Anatomy 0.000 description 1
229940094443 oxytocics prostaglandins Drugs 0.000 description 1
238000007427 paired t-test Methods 0.000 description 1
230000003076 paracrine Effects 0.000 description 1
208000012111 paraneoplastic syndrome Diseases 0.000 description 1
230000000849 parathyroid Effects 0.000 description 1
201000003686 parathyroid adenoma Diseases 0.000 description 1
208000014643 parathyroid gland adenoma Diseases 0.000 description 1
108010053339 parathyroid hormone (1-11) Proteins 0.000 description 1
108010073677 parathyroid hormone (1-30) Proteins 0.000 description 1
108010073509 parathyroid hormone (1-31) Proteins 0.000 description 1
208000025061 parathyroid hyperplasia Diseases 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
239000002245 particle Substances 0.000 description 1
239000001814 pectin Substances 0.000 description 1
235000010987 pectin Nutrition 0.000 description 1
229920001277 pectin Polymers 0.000 description 1
239000008188 pellet Substances 0.000 description 1
230000002085 persistent effect Effects 0.000 description 1
239000008177 pharmaceutical agent Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
238000005191 phase separation Methods 0.000 description 1
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
229940085991 phosphate ion Drugs 0.000 description 1
150000003904 phospholipids Chemical class 0.000 description 1
230000026731 phosphorylation Effects 0.000 description 1
238000006366 phosphorylation reaction Methods 0.000 description 1
230000037081 physical activity Effects 0.000 description 1
230000035479 physiological effects, processes and functions Effects 0.000 description 1
230000001817 pituitary effect Effects 0.000 description 1
210000002826 placenta Anatomy 0.000 description 1
238000013001 point bending Methods 0.000 description 1
229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
229920001515 polyalkylene glycol Polymers 0.000 description 1
229920001896 polybutyrate Polymers 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229920001155 polypropylene Polymers 0.000 description 1
210000002729 polyribosome Anatomy 0.000 description 1
230000008092 positive effect Effects 0.000 description 1
208000001685 postmenopausal osteoporosis Diseases 0.000 description 1
230000002980 postoperative effect Effects 0.000 description 1
230000001323 posttranslational effect Effects 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
229940063238 premarin Drugs 0.000 description 1
230000002028 premature Effects 0.000 description 1
108010022328 proparathormone Proteins 0.000 description 1
150000003180 prostaglandins Chemical class 0.000 description 1
108060006633 protein kinase Proteins 0.000 description 1
230000017854 proteolysis Effects 0.000 description 1
230000002294 pubertal effect Effects 0.000 description 1
238000011046 pyrogen test Methods 0.000 description 1
238000012113 quantitative test Methods 0.000 description 1
206010037844 rash Diseases 0.000 description 1
238000011084 recovery Methods 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
230000008085 renal dysfunction Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
108010068072 salmon calcitonin Proteins 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
238000012216 screening Methods 0.000 description 1
CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
230000009991 second messenger activation Effects 0.000 description 1
230000009291 secondary effect Effects 0.000 description 1
210000004739 secretory vesicle Anatomy 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
208000013220 shortness of breath Diseases 0.000 description 1
231100001055 skeletal defect Toxicity 0.000 description 1
230000009645 skeletal growth Effects 0.000 description 1
229940112726 skelid Drugs 0.000 description 1
210000002460 smooth muscle Anatomy 0.000 description 1
239000000344 soap Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
239000007787 solid Substances 0.000 description 1
238000001179 sorption measurement Methods 0.000 description 1
206010041569 spinal fracture Diseases 0.000 description 1
238000013223 sprague-dawley female rat Methods 0.000 description 1
238000012453 sprague-dawley rat model Methods 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
238000007655 standard test method Methods 0.000 description 1
238000000547 structure data Methods 0.000 description 1
239000013589 supplement Substances 0.000 description 1
230000008093 supporting effect Effects 0.000 description 1
239000000829 suppository Substances 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
238000012353 t test Methods 0.000 description 1
229960005460 teriparatide Drugs 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
239000003451 thiazide diuretic agent Substances 0.000 description 1
210000001694 thigh bone Anatomy 0.000 description 1
239000010409 thin film Substances 0.000 description 1
239000003106 tissue adhesive Substances 0.000 description 1
238000011200 topical administration Methods 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
238000013417 toxicology model Methods 0.000 description 1
230000002463 transducing effect Effects 0.000 description 1
230000009466 transformation Effects 0.000 description 1
206010044412 transitional cell carcinoma Diseases 0.000 description 1
230000001296 transplacental effect Effects 0.000 description 1
238000011269 treatment regimen Methods 0.000 description 1
229940078499 tricalcium phosphate Drugs 0.000 description 1
229910000391 tricalcium phosphate Inorganic materials 0.000 description 1
235000019731 tricalcium phosphate Nutrition 0.000 description 1
230000001960 triggered effect Effects 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
239000012588 trypsin Substances 0.000 description 1
238000007492 two-way ANOVA Methods 0.000 description 1
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
210000000623 ulna Anatomy 0.000 description 1
238000005199 ultracentrifugation Methods 0.000 description 1
238000011870 unpaired t-test Methods 0.000 description 1
238000011144 upstream manufacturing Methods 0.000 description 1
239000004474 valine Substances 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
102000009310 vitamin D receptors Human genes 0.000 description 1
108050000156 vitamin D receptors Proteins 0.000 description 1
150000003722 vitamin derivatives Chemical class 0.000 description 1
230000008673 vomiting Effects 0.000 description 1
238000005406 washing Methods 0.000 description 1
229940002005 zometa Drugs 0.000 description 1